Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01634-9
Abstract: Netarsudil reduces intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM) pathway and decreasing episcleral venous pressure. The primary objective of this phase 2 study was to evaluate ocular hypotensive efficacy and… read more here.
Keywords: study; japanese patients; iop; patients primary ... See more keywords
Netarsudil Ophthalmic Solution 0.02%: First Global Approval
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0877-7
Abstract: Netarsudil ophthalmic solution 0.02% (hereafter referred to as netarsudil 0.02%) [Rhopressa®] is a Rho-associated protein kinase inhibitor that is thought to lower intraocular pressure (IOP) by increasing aqueous humour outflow through the trabecular meshwork. It… read more here.
Keywords: solution first; ophthalmic solution; netarsudil ophthalmic; first global ... See more keywords
Effects of 0.02% netarsudil ophthalmic solution on intraocular pressure of normotensive dogs.
Sign Up to like & getrecommendations! Published in 2020 at "Veterinary ophthalmology"
DOI: 10.1111/vop.12736
Abstract: OBJECTIVES To evaluate the effect of QD or BID 0.02% netarsudil ophthalmic solution (Aerie Pharmaceuticals) on intraocular pressure (IOP) in normotensive dogs and to describe any adverse effects. ANIMALS STUDIED Normotensive Labrador retriever dogs were… read more here.
Keywords: intraocular pressure; day dosing; ophthalmic solution; netarsudil ophthalmic ... See more keywords